Skip to main content
Signal8
Launch Terminal
LUCI DAVID P profile photo

David P. Luci

CIK: 0001271123

Transaction Breakdown

Open Market Buys (P)1 (33.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Acurx Pharmaceuticals, Inc. logo
ACXP

Acurx Pharmaceuticals, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

  • Acurx Pharmaceuticals, Inc. logo
    ACXP

    Acurx Pharmaceuticals, Inc.

    Apr 20, 2026
    Award(A)

    Stock Option

    Direct
    37.1K shares-
  • Acurx Pharmaceuticals, Inc. logo
    ACXP

    Acurx Pharmaceuticals, Inc.

    Feb 5, 2025
    Award(A)

    Stock Option

    Direct
    250K shares-
  • Acurx Pharmaceuticals, Inc. logo
    ACXP

    Acurx Pharmaceuticals, Inc.

    Jan 6, 2025
    Purchase(P)
    Direct
    49.3K shares at avg. $1.01$50K

1-3 of 3

About LUCI DAVID P

LUCI DAVID P (SEC CIK 0001271123) files insider reports with the SEC as President and CEO of Acurx Pharmaceuticals, Inc. (ACXP).

Signal8 holds 3 ownership filings by LUCI DAVID P, all Form 4s, filed between Jan 8, 2025 and Apr 22, 2026. Those filings report 3 transactions, from Jan 6, 2025 to Apr 20, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on LUCI DAVID P's filings is in STATEN ISLAND, NY.

Recent filings by LUCI DAVID P

  • Apr 20, 2026: Grant or award of ACXP derivative securities (Form 4, code A).
  • Feb 5, 2025: Grant or award of ACXP derivative securities (Form 4, code A).
  • Jan 6, 2025: Open-market purchase of ACXP shares (Form 4, code P).

Other insiders filing for Acurx Pharmaceuticals, Inc. (ACXP)

How to read Form 4 transaction codes